Scholars Central

ArticlePublished 2015

The relationship between HDL-associated PON1 activity, oxidative stress and brain natriuretic peptide in NYHA functional class ii-iv heart failure patients.

Authors: Esin Eren, Hamit Yasar Ellidag, Ozgur Aydin, Selcuk Kucukseymen, Ozlem Giray, Sakir Aslan, Necat Yilmaz

Biomedical Research

Volume 26 · Issue 3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

As the role of oxidative stress on human diseases, including the cardiovascular system disorders, has accentuated, the ultimate need of reliable markers of oxidative stress becomes more imperative. We aimed to measure: activities of HDL-associated antioxidant enzymes, paraoxonase (PON1) and arylesterase (ARE); total oxidative (TOS) and antioxidative status (TAS), in heart failure (HF) patients, and search for correlations of these markers. The study group consisted of 70 subjects with HF. The patients were classified in three groups according to the suggestions of New York Heart Association. Serum levels of PON1, ARE, TOS, TAS, brain natriuretic peptide (BNP), uric acid (UA), creatinine, and lipid parameters were determined. The oxidative status index (OSI) was calculated. Plasma PON1 activity was significantly decreased (p=0.04), while BNP and UA levels were significantly increased(p<0.0001, p= 0.03, respectively), with the severity of the disease. ARE, TAS, TOS, and OSI did not show any statistically significant difference. Statistical analysis showed negative correlation between PON1, ARE activities and BNP; positive correlation between disease duration, UA and BNP. Also, a positive correlation was determined between TAS and UA. We report for the first time a notable relationship between HDL-associated anti-oxidant PON-1 activity and New York Heart Association classification for HF .These prominent results provide further support for the role for oxidative processes in the disease progression of HF and for the anti-oxidant compensatory role of HDL. We believe in the potential of antioxidant medications in HF and promote proper oxidative stress markers in routine use in diagnosis and follow-up.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Biomedical Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalBiomedical Research
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Esin Eren”
  • BylineArticles whose byline prints “Hamit Yasar Ellidag”
  • BylineArticles whose byline prints “Ozgur Aydin”
  • BylineArticles whose byline prints “Selcuk Kucukseymen”
  • BylineArticles whose byline prints “Ozlem Giray”
  • BylineArticles whose byline prints “Sakir Aslan”
  • BylineArticles whose byline prints “Necat Yilmaz”